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Summary. A simple and sensitive liquid chromatography–tandem mass spectrometry 
method was developed for the quantification of atorvastatin, ortho-hydroxyatorvastatin, 
para-hydroxyatorvastatin, and atorvastatin lactone in rat plasma. Solid-phase extraction 
was used for preparation of samples. Rosuvastatin was chosen as an internal standard. 
Chromatographic separation was achieved on ZORBAX Eclipse C18 Analytical, 4.6 × 100 
mm (3.5 μm) column with a gradient mobile phase composed of acetonitrile and 0.1% 
acetic acid, at a flow rate of 400 μL min−1. The column was kept at constant temperature 
(25 °C), and autosampler tray temperature was set at 4 °C. The following selected reac-
tion monitoring (SRM) transitions were selected: (m/z, Q1 → Q3, collision energy) 
atorvastatin (559.47 → 440.03, 22 eV), atorvastatin lactone (541.36 → 448.02, 19 eV), ortho-
hydroxyatorvastatin (575.20 → 440.18, 20 eV), para-hydroxyatorvastatin (575.54 → 440.18, 
20 eV), and rosuvastatin (482.25 with selected combination of two fragments 257.77, 31 
eV, and 299.81, 35 eV) in positive ion mode. The method was validated over a concentra-
tion range of 0.5–20 ng mL−1 for ortho-hydroxyatorvastatin and para-hydroxyatorvastatin 
and 0.1–20 ng mL−1 for atorvastatin and atorvastatin lactone with excellent linearity (r2 ≥ 
0.99). This method demonstrated acceptable precision and accuracy at four quality con-
trol concentration levels. The detection limits were 0.1 and 0.13 ng mL−1 for ortho-
hydroxyatorvastatin and para-hydroxyatorvastatin, respectively, and 0.05 ng mL−1 for 
atorvastatin and atorvastatin lactone. All analytes were found to be stable at examined 
conditions. Validated method was applied for determination of atorvastatin and its me-
tabolites in plasma of experimental animals. 
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Introduction 
 
According to published data, cardiovascular diseases are the leading cause 
of death in developed countries [1]. The major cause of coronary heart dis-
ease is increased intake of food rich in cholesterol. Statins (3-hydroxy-3-
methylglutaryl-coenzyme A [HMG-CoA] reductase inhibitors) are widely 
used for the treatment of hypercholesterolemia. They reversibly inhibit 
HMG-CoA reductase which is the rate-limiting enzyme in the endogenous 
biosynthesis of cholesterol. Statins also have many cholesterol-independent 
(“pleiotropic”) beneficial effects. One of the most important is their antioxi-
dative activity [2–4]. Although the side effects of statins are relatively low, 
they can cause rhabdomyolysis in rare cases [5]. This fact increases impor-
tance of monitoring atorvastatin (AT) levels in biological fluids. 
Atorvastatin is administered as the calcium salt of its active acid form 
and undergoes extensive first-pass metabolism [6]. It is metabolized in liver 
by CYP3A4 to two active hydroxy metabolites, ortho-hydroxyatorvastatin 
(oOH-AT) and para-hydroxyatorvastatin (pOH-AT), and three correspond-
ing lactones (Fig. 1) [7]. HMG-CoA reductase inhibitory activity is mainly 
(around 70%) attributed to active metabolites [8]. The plasma concentration 
of active and inactive metabolites as well as parent drug is very low 
(nanogram per milliliter levels). Therefore, a bioanalytical method that is 
going to be used for the quantification of atorvastatin and its metabolites 
needs low limits of detection and quantitation. 
There are published methods for the quantification of AT in biological 
matrix, pharmaceutical products, and bulk drugs. Some of those methods 
include enzyme inhibition assay [9], radioimmunoassay [10], electrochemi-
cal method [11], high-performance liquid chromatography (HPLC) with ul-
traviolet (UV) detection [12–15], liquid chromatography–mass spectrometry 
[16], microbore liquid chromatography/electrospray ionization–tandem 
mass spectrometry [17], and liquid chromatography–tandem mass spec-
trometry (LC–MS/MS) [18–27]. Immunoassay methods lack specificity and, 
in some cases, are subject to problems with cross-reactive interferences. 
Also, enzyme inhibition assay is relevant when determining the HMG-CoA 
reductase inhibitory activity of AT in plasma, but it does not give any further 
information about metabolites. 
 Information about plasma concentration of parent drug and active and 
inactive metabolites is of interest in various types of studies, especially for 
investigations of possible drug–drug or drug–natural product interactions, 
pharmacokinetic studies, and side effects and toxicity of metabolites. 
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Fig. 1. Metabolism scheme of atorvastatin 
 
The aim of this study was to develop and validate simple and sensitive 
LC–MS/MS method for quantification of atorvastatin and its metabolites in 
plasma samples obtained from experimental animals orally treated with 
atorvastatin for 6 weeks. 
 
Experimental 
 
Reagents and Chemicals 
 
Atorvastatin (99.87%), o-hydroxyatorvastatin (99.92%), p-hydroxyator-
vastatin (99.97%), and atorvastatin lactone (AT-L, 99.89%) were provided by 
Nobel Ilaç Company (Istanbul, Turkey). Purity of standards was deter-
mined by manufacturers by high-performance liquid chromatography 
(HPLC) method. Unfortunately, we were not able to obtain reference stan-
dards of o-hydroxyatorvastatin lactone and p-hydroxyatorvastatin lactone 
for method validation, so this method excluded these two metabolites. 
Deuterated analogs of atorvastatin and its metabolites, which are known to 
be the most suitable for LC–MS methods, were not available, and rosuvas-
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tatin (Medicines and Medical Devices Agency, Belgrade, Serbia) was used 
as internal standard. HPLC-grade acetonitrile and glacial acetic acid were 
obtained from J.T.Baker (Deventer, Netherlands). Ammonium acetate used 
for preparation of buffers was purchased from Merck (Darmstadt, Ger-
many). Ultrapure water was obtained by means of a TKA Water purifica-
tion system (Niederelbert, Germany). 
 
Preparation of Standard Samples 
 
Stock solutions of atorvastatin, o-hydroxyatorvastatin, p-hydroxyator-
vastatin, and rosuvastatin were prepared by separately dissolving 5 mg of 
each substance in a mixture of acetonitrile and water (10 mL, 90:10, v/v). 
Stock solution of atorvastatin lactone was prepared by dissolving 5 mg in 
acetonitrile (5 mL). These stock solutions were divided into 500-μL portions 
and stored at −8 °C until further use. For method validation, 500-μL por-
tions of AT, oOH-AT, pOH-AT, and internal standard (IS) stock solutions 
were thawed and then separately freshly diluted to 50 mL with 100 mM 
ammonium acetate buffer, pH 4.6 (pH was adjusted with glacial acetic acid). 
A 500-μL portion of AT-L stock solution was diluted to 50 mL with 100 mM 
ammonium acetate buffer, pH 4.6. Five milliliters of this solution was fur-
ther diluted to 10 mL with same buffer. The concentrations of all analytes in 
prepared solutions were 5 μg mL−1. Method optimization was conducted 
with solutions prepared by separately diluting 1 mL of 5 μg mL−1 solutions 
with buffer to the concentration of 50 ng mL−1. Calibration standards were 
prepared by diluting 50 ng mL−1 standard solutions to obtain concentrations 
in range of 0.1–20 ng mL−1 for AT and AT-L and 0.5–20 ng mL−1 for oOH-
AT and pOH-AT. Internal standard working solution was prepared sepa-
rately by diluting 200 μL of 5 μg mL−1 solution to 10 mL with buffer to ob-
tain concentration of 100 ng mL−1. All solutions were kept on ice to mini-
mize interconversion of lactone and acid forms. Heparin drug-free plasma 
was obtained from six animals. Calibration standards and quality control 
samples were prepared by spiking drug-free plasma with aliquots of the 
working standard solution. 
 
 
Biological Samples 
 
Male Wistar albino rats were used for the experiment. Animals were ob-
tained from the Military Medical Academy Farm (Belgrade, Serbia). Animal 
blood samples were collected directly from the heart in test tubes containing 
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heparin and centrifuged 3000 rpm for 15 min. Plasma samples were frozen 
immediately after sample withdrawal to minimize acid–lactone intercon-
version and stored at −80 °C. All experimental procedures and protocols 
conformed to institutional guidelines for the care and use of animals in re-
search no. 5/10 (Ethics Committee of the Faculty of Pharmacy, University of 
Belgrade).  
 
Instrumentation 
 
Analyses were carried out on an ultra-high performance liquid chromatog-
raphy (UHPLC)–MS/MS system consisting of a Thermo ACCELA UHPLC 
(Thermo Scientific, Waltham, MA, USA) coupled to a triple quad Mass 
Spectrometer Thermo TSQ Quantum Access Max (Thermo Scientific, 
Waltham, MA, USA) with a heated electrospray ionization (HESI) interface 
operated in the positive mode. All data were acquired and processed by 
Xcalibur software (Thermo Fisher, San Jose, CA, USA). EBA 8S (Hettich 
Zentrifugen, Tuttlingen, Germany) was used in sample preparation. SPE 
procedure was carried out on Baker spe-12G manifold (J.T.Baker, Deventer, 
Netherlands). A ZORBAX Eclipse C18 Analytical, 4.6 × 100 mm (3.5 μm) col-
umn (Agilent, Santa Clara, CA, USA), was used for the chromatographic 
separation of the compounds. The column was kept at constant temperature 
at 25 °C, and autosampler tray temperature was set at 4 °C to minimize pos-
sible interconversion between acid and lactone forms. The analytes were 
eluted by a gradient mobile phase system which consisted of acetonitrile 
(channel A) and 0.1% CH3COOH (channel B) (Table I). The flow rate was 
constantly kept on 400 μL min−1. The mass spectrometer was operated in 
positive ion mode and connected to the chromatographic system using an 
ESI interface. Tuning the MS detector for optimal operating conditions to 
get low limit of quantification (LOQ) was achieved through infusion of 
standard mixture (including internal standard) in 50 ng mL−1 concentration 
through a T-connector. Collision gas was argon. Spray voltage was set on 
5500 V; vaporizer temperature at 250 °C; sheath gas pressure, 40 units; ion 
sweep gas pressure, 0 units; auxiliary gas pressure, 10 units; capillary tem-
perature, 250 °C; capillary offset, 35; tube lens offset, 78; and skimmer offset, 
−6. The MS detector was operated in the selected reaction monitoring (SRM) 
mode with the following SRM transitions: (m/z, Q1 → Q3, collision energy) 
of AT (m/z, 559.47 → 440.03, 22 eV), AT-L (m/z, 541.36 → 448.02, 19 eV), 
oOH-AT (m/z, 575.20 → 440.18, 20 eV), pOH-AT (m/z, 575.54 → 440.18, 20 
eV), and IS (m/z, 482.25 with selected combination of two fragments to im-
prove signal 257.77, 31 eV, and 299.81, 35 eV). 
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Table I. Gradient mobile phase 
t %A %B 
0 65 35 
4 65 35 
4.5 80 20 
7 80 20 
7.05 65 35 
8 65 35 
A — acetonitrile; B — 0.1% CH3COOH 
 
 
Sample Preparation 
 
Samples were prepared by solid-phase extraction and kept on ice at all 
times. Calibration standards and quality control (QC) samples were pre-
pared by mixing 500 μL of drug-free plasma with 50 μL of internal standard 
(IS) working solution and adequate amount of 50 ng mL−1 working stan-
dard solution and diluted with ammonium acetate (0.1 M, pH 4.6) to 
achieve total volume of 1 mL. Samples were further vortexed and centri-
fuged at 1600g for 5 min. The supernatant was subsequently transferred to  
1 mL OASIS® HLB SPE cartridges (Waters, Milford, Massachusetts, USA), 
preconditioned with 2 mL acetonitrile followed by 2 mL water. The car-
tridges were washed with 1 mL water and 1 mL acetonitrile–water (5:95, 
v/v). The analytes were eluted with 1 mL acetonitrile–ammonium acetate 
buffer (0.1 M, pH 4.6, 95:5, v/v). Pure extracts were directly transferred to 
autosampler vials. 
Plasma samples of animals that received atorvastatin were prepared by 
mixing 500 μL of plasma with 50 μL of internal standard (IS) working solu-
tion and diluted with ammonium acetate (0.1 M, pH 4.6) to achieve total 
volume of 1 mL. Samples were further vortexed, centrifuged, and trans-
ferred to SPE cartridges in same manner as calibration standards and qual-
ity control (QC) samples. 
 
Method Validation 
 
The method was validated according to the bioanalytical method validation 
guidelines of the European Medicines Agency [28] and Food and Drug 
Administration [29]. Validation was performed by analyzing calibration 
and quality control standards to demonstrate acceptable within run and be-
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tween run accuracy and precision over the desired range of concentration. 
Quantification was based on ratio of peak areas of investigated analytes and 
peak area of internal standard. A batch included six standard levels span-
ning the concentration range from 0.1 to 20 ng mL−1 for atorvastatin and 
atorvastatin lactone and 0.5 to 20 ng mL−1 for ortho-hydroxyatorvastatin and 
para-hydroxyatorvastatin, blank (plasma without analytes and IS) and zero 
(plasma without analytes, with IS) samples. Quality control samples at four 
concentration levels (0.1, 0.3, 10, and 15 ng mL−1 for AT and AT-L and 0.5, 1, 
10, and 15 ng mL−1 for oOH-AT and pOH-AT) were used for determination 
of within-run and between-run accuracy, precision, and recovery.  
 
 
Selectivity and specificity 
 
The selectivity of the method was determined with six different blank rat 
plasma samples, which were analyzed to test the potential interferences of 
endogenous compounds coeluting with analytes and IS. Chromatographic 
peaks of analytes and IS were identified based on their retention times and 
SRM responses. The peak area of interferences in blank samples should not 
be more than 20% of the mean peak area at LOQ levels. 
 
 
Matrix effect 
 
In order to evaluate possible ion suppression due to the matrix effect, blank 
rat plasma samples obtained from six different sources were extracted and 
spiked to the concentration of 5 ng mL−1. These samples were injected with 
samples containing no matrix components. 
 
 
Linearity 
 
Calibration curves were obtained by linear regression. Weighted linear re-
gression was previously performed, and best results were achieved with 
weighting factor of 0, which led to the conclusion that no weighting was 
necessary. The ratio of analytes peak area to IS peak area was plotted 
against analytes concentration in nanograms per milliliter. Calibration curve 
standard samples and quality control samples were prepared in replicates 
(n = 5) for analysis. The obtained correlation coefficient was higher than 
0.9950. 
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Precision and accuracy 
 
Precision and accuracy should be within ≤15% and ±15% of their nominal 
values. For lower limit of quantification (LLOQ), the precision and accuracy 
should be within ≤20% and ±20%. 
 
Stability 
 
Stability testing was evaluated with low (LQC) and high (HQC) level con-
centration of quality control sample (LQC; 0.3 ng mL−1 for AT and AT-L and 
1 ng mL−1 for oOH-AT and pOH-AT; HQC: 15 ng mL−1 for all compounds). 
Autosampler stability was determined by keeping samples in autosampler 
at 4 °C for 24 h. Bench-top stability was evaluated by keeping LQC and 
HQC at the same conditions as samples from experimental animals for 8 h. 
Long-term stability was checked after keeping QC samples at −80 °C for 1 
month. Freeze and thaw stability was tested in freshly spiked HQC and 
LQC samples that were stored at −80 °C for 12 h and then were thawed on 
ice bath. 
 
Extraction efficiency 
 
Determination of the extraction efficiency was performed by comparing the 
response of extracted samples spiked before extraction and the response of 
extracted blank samples spiked before injection to LC–MS. A recovery of 
more than 50% was considered adequate. 
 
 
LLOQ and LOD 
 
LLOQ was determined at a signal-to-noise (S/N) ratio of 10:1. LOD was de-
termined using S/N ratio of 3:1 by comparing test results from samples 
with known concentrations of analyte with those from the blank samples. 
 
Results and Discussion 
 
Optimization of Solid-Phase Extraction (SPE) Procedure 
 
Preparation of plasma samples is the most important step in method devel-
opment. Liquid–liquid extraction is time consuming, and protein precipita-
tion leads to significant ion suppression in mass spectrometry. Solid-phase  
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Fig. 2. Ionization profiles of A — atorvastatin, B — ortho-hydroxyatorvastatin,  
C — para-hydroxyatorvastatin, and D — atorvastatin lactone; pH range: 1–12 
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extraction is a simple and fast method which produces clean samples with 
no significant matrix effect. Plasma samples were mixed with ammonium 
acetate buffer, pH 4.6 (0.1 M) in order to minimize possible interconversion 
between acid and lactone forms [30]. Carboxylic group in structure of AT, 
oOH-AT, and pOH-AT has pKa value of 4.33. At chosen pH, AT, oOH-AT, 
and pOH-AT are 65% in ionized and 35% in unionized form, and AT-L is 
100% in unionized form (does not have acidic group in structure). Distribu-
tion of ionized and unionized forms of analyzed compounds at pH range  
1–12 is shown in Fig. 2. 
OASIS® HLB cartridges were chosen since they are acceptable for both 
hydrophilic and lipophilic compounds. Comparing to mostly used C18 car-
tridges, these cartridges have advantage — they are simpler for use and 
they can dry out during extraction procedure. First wash step was carried 
out with water since analytes of interest are not soluble in water. Second 
wash step with 5% acetonitrile gave cleaner samples and better recoveries 
than washing with same percentage of methanol. Washing cartridges with 
higher percentage of acetonitrile would give lower recoveries since all ana-
lytes are soluble in this solvent. The procedure of extraction analytes from 
cartridges was examined with a different mixture: acetonitrile and buffer in 
different ratios and mixture of methanol and buffer, but mixture of acetoni-
trile and ammonium acetate buffer, pH 4.6 (0.1 M; 95:5, v/v), gave the high-
est recoveries. 
Elution was completely performed with 1 mL of mixture. Extracts were 
filtered and transferred to LC–MS vial without further concentration steps. 
 
LC–MS/MS Determination 
 
LC–MS/MS conditions were set in order to get the best chromatographic 
separations and the best possible sensitivity of the method. Good chroma-
tographic separation was important since pOH-AT and oOH-AT have the 
same precursor → ion-product transitions and because of possible acid–
lactone interconversion. There are some articles describing isocratic separa-
tion of some of the investigated compounds, but they do not include inves-
tigation of lactone [27], run is 20 min [21], or precipitation of proteins was 
used instead of SPE [26]. 
Isocratic elution with mobile phase (0.1% CH3COOH–acetonitrile; 
35:65, v/v) was tested. Good separation was achieved, but run lasted con-
siderably longer. In order to shorten run time and keep good separation, 
gradient mobile phase was used. The total time of analysis in the chroma-
tographic system was 8 min, including the time for reequilibration. The re-
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tention times of investigated compounds were: 2.60 (pOH-AT), 3.88 (oOH-
AT), 4.48 (AT), 6.15 (AT-L), and 3.05 for rosuvastatin. Chromatogram at 
LLOQ levels is shown in Fig. 3, and chromatogram of a plasma sample 
taken from rats after 6 weeks of daily atorvastatin intake is shown in Fig. 4. 
 
 
Fig. 3. Chromatogram at LOQ level of: A — internal standard (rosuvastatin),  
B — atorvastatin lactone, C — atorvastatin, and D — para-hydroxyatorvastatin and  
ortho-hydroxyatorvastatin. Peaks of analytes of interest are marked 
 
 
Fig. 4. Chromatogram of a plasma sample taken from rats after 6 weeks of daily 
atorvastatin intake (A — internal standard (rosuvastatin), B — atorvastatin lactone,  
C — atorvastatin, and D — para-hydroxyatorvastatin and ortho-hydroxyatorvastatin) 
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Fig. 5. Fragmentation pattern of: A — atorvastatin, B — ortho-hydroxyatorvastatin,  
C — para-hydroxyatorvastatin, D — atorvastatin lactone, and E — rosuvastatin (IS) 
(chosen fragments are marked) 
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The MS/MS was operated using electrospray ionization probe in posi-
tive ion mode. Protonated molecular ion ([M+H]+) was the major parent ion 
used to obtain the product ion spectra for all compounds. MS source pa-
rameters were optimized based on pOH-AT since its concentration in 
plasma is lower than other analytes. All parameters were optimized to 
achieve maximum signal. Fragmentation pattern of all tested compounds is 
shown in Fig. 5. 
 
Method Validation 
 
Validated method showed linearity within the concentration range of  
0.5–20 ng mL−1 for ortho-hydroxyatorvastatin and para-hydroxyatorvastatin 
and 0.1–20 ng mL−1 for atorvastatin and atorvastatin lactone (r2 ≥ 0.99, n = 6 
for oOH-AT and pOH-AT and n = 7 for AT and AT-L). Calibration curve 
data are shown in Table II. Student t-test confirmed that the intercepts of the 
calibration curves were not statistically different from zero for any of the 
analytes. Determined LOD was 0.1 and 0.13 ng mL−1 for oOH-AT and pOH-
AT, respectively, and 0.05 ng mL−1 for AT and AT-L. Lowest concentration 
on calibration curve was LLOQ. Extraction efficiencies were between 57% 
and 75% for all analytes, which is acceptable for bioanalytical methods. 
 
Table II. Parameters of calibration curve for atorvastatin, atorvastatin lactone, para-
hydroxyatorvastatin, and ortho-hydroxyatorvastatin in rat plasma (n = 5) 
Analyte Slope Intercept Coefficient of correlation (r) 
Atorvastatin 1.9478 −0.0670 0.9982 
Atorvastatin lactone 1.6274 −0.1257 0.9993 
para-Hydroxyatorvastatin 0.2380 −0.1998 0.9963 
ortho-Hydroxyatorvastatin 0.3545 −0.2443 0.9978 
 
Within-run and between-run precision was presented as %CV and was 
lower than 15% for all analyzed samples. At some points, values were very 
close to 15, but that was acceptable because of very labile nature of analytes 
and easily undergoing to interconversion. Within-run and between-run ac-
curacy was calculated as percentage of nominal concentration of controlled 
samples. Results were within acceptance criteria (±15% for all QC except for  
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Table III. Precision and accuracy of the LC–MS method for atorvastatin, atorvastatin 
lactone, para-hydroxyatorvastatin, and ortho-hydroxyatorvastatin in rat plasma (n = 5) 
Within run (n = 5) Between run (n = 3) 
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0.1 0.09 ± 0.01 14.50 90.58 0.10 ± 0.01 11.49 104.30 
0.3 0.27 ± 0.02 9.69 89.27 0.27 ± 0.03 14.56 89.66 
 10 11.46 ± 1.86 14.34 114.63 11.35 ± 1.35 12.83 113.46 
Atorvastatin 
 15 16.57 ± 1.32 7.56 110.45 16.20 ± 2.01 9.57 108.01 
0.1 0.12 ± 0.01 11.25 117.99 0.11 ± 0.01 11.13 111.66 
0.3 0.28 ± 0.04 14.29 93.31 0.27 ± 0.03 11.11 90.79 
 10 11.58 ± 1.08 9.33 114.77 11.46 ± 1.37 9.89 114.59 
Atorvastatin lac-
tone 
 15 16.77 ± 0.08 0.48 111.78 16.35 ± 1.42 8.68 109.00 
0.5 0.58 ± 0.01 1.19 116.00 0.59 ± 0.05 8.47 117.00 
1 1.06 ± 0.10 8.75 105.62 1.06 ± 0.09 8.49 106.20 
 10 9.57 ± 0.01 0.12 95.71 9.62 ± 0.87 9.04 96.19 
para-
Hydroxyatorvas-
tatin 
 15 14.67 ± 0.46 3.71 97.79 15.33 ± 1.43 9.33 102.20 
0.5 0.57 ± 0.01 1.03 114.01 0.57 ± 0.01 1.75 115.11 
1 0.87 ± 0.10 11.47 86.56 0.92 ± 0.03 3.26 91.83 
 10 8.75 ± 0.88 10.02 87.52 11.23 ± 1.34 11.93 112.32 
ortho-
Hydroxyatorvas-
tatin 
 15 15.65 ± 2.55 14.88 104.36 15.28 ± 1.73 11.32 101.86 
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LLOQ, where ±20% is allowed). All accuracy and precision results are 
shown in Table III. 
The specificity of the method was tested using drug-free plasma from 
six animals. No interfering peaks and no matrix effect were found for any of 
the analytes. Chromatograms of blanco (without analytes and IS) and zero 
(without analytes but with IS) are shown in Fig. 6. 
 
 
 
Fig. 6. Chromatograms of: 1 — blanco (without analytes and IS) sample and 2 — zero 
(without analytes but with IS) sample (A — internal standard [rosuvastatin],  
B — atorvastatin lactone, C — atorvastatin, and D — para-hydroxyatorvastatin and  
ortho-hydroxyatorvastatin) 
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Stability of analytes was tested through three different levels: short-
term stability, freeze–thaw stability, and long-term stability. The obtained 
results were between 92% and 103% for all tested conditions. 
 
 
Method Application 
 
This method was successfully applied to determine concentrations of AT, 
AT-L, oOH-AT, and pOH-AT in rat plasma after administration of atorvas-
tatin for 6 weeks. The aim of this animal study was monitoring changes in 
plasma concentration of atorvastatin and its active and inactive metabolites 
as a result of its interaction with other drugs and natural products used for 
treatment of hyperlipidemia. Results obtained from plasma samples of ex-
perimental animals treated with atorvastatin and combination of atorvas-
tatin and artichoke leaf extract (whose effects were investigated in this 
study) are shown in Table IV. Plasma samples were spiked with internal 
standard and extracted as described in experimental procedure. Figure 4 
shows one of the chromatograms from experimental animal treated with 
atorvastatin. 
 
Table IV. Concentrations of atorvastatin and its metabolites in plasma samples of rats 
treated with atorvastatin and combination of atorvastatin and artichoke leaf extract 
Treatment 
Analyte 
AT AT + artichoke leaf extract 
p 
AT (ng mL−1) 0.5052 ± 0.3585 0.1455 ± 0.0716 <0.05 
oOH-AT (ng mL−1) 0.2363 ± 0.3542 0.1025 ± 0.0168   0.377 
pOH-AT (ng mL−1) 1.0049 ± 0.1182 0.8441 ± 0.0709 <0.05 
AT-L (ng mL−1) 0.8437 ± 0.0253 0.9527 ± 0.1034 <0.05 
 
 
Conclusions 
 
The aim of this study was to establish LC–MS/MS method for monitoring 
changes in plasma concentration of atorvastatin and its active and inactive 
metabolites. 
Method was validated according to bioanalytical method validation 
guidelines. Comparing to previously published method, the advantage of 
this method is determination of inactive lactone as well as active hydroxy 
metabolites, using SPE procedure instead of protein precipitation and short 
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run time. The described method is sensitive, simple, and reliable and was 
successfully used for further evaluation of the interaction of atorvastatin 
with artichoke leaf extract, which is often used for treatment of hyperlipi-
demia. 
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